Trial Profile
Phase II Study of Pembrolizumab (MK-3475) With and Without Bevacizumab for Recurrent Glioblastoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Pembrolizumab (Primary)
- Indications Glioblastoma; Gliosarcoma
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 16 Nov 2020 Primary endpoint has been met. (6-Month Progression-Free Survival (PFS6))
- 16 Nov 2020 Results published in the Clinical Cancer Research
- 21 May 2019 Status changed from active, no longer recruiting to completed.